Krystal Biotech Inc (Krystal Biotech) is a gene therapy company that carries out the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, especially dermatological diseases. The company’s only marketed product is VYJUVEK/B-VEC (bercolagene telserpavec), which is a gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech uses its patented gene therapy technology platform based on engineered HSV-1 to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The company’s pipeline products include KB105, KB407, KB104, KB408, and KB707. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.
Headquarters
United States of America
Address
2100 Wharton St Ste 701, Pittsburgh, Pennsylvania, 15203-1973
Website
www.krystalbio.com
Telephone
1 412 5865830
No of Employees
229
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KRYS (NASD)
Revenue (2022)
$50.7M
EPS
XYZ
Net Income (2022)
XYZ
107.8%
(2022 vs 2021)
Market Cap*
$4.7B
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Krystal Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| VYJUVEK (B-VEC- Bercolagene Telserpavec): | VYJUVEK |
| Dystrophic Epidermolysis Bullosa (DEB) | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy. |
| 2023 | Regulatory Approval | In December, the company received Orphan Drug Designation (ODD) from the Japan Ministry of Health, Labour and Welfare (MHLW) for beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB). |
| 2023 | Regulatory Approval | In September, the company received the Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD). |
Competitor Comparison
| Key Parameters | Krystal Biotech Inc | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Pittsburgh | New Brunswick | Kenilworth | New York | North Chicago |
| State/Province | Pennsylvania | New Jersey | New Jersey | New York | Illinois |
| No. of Employees | 229 | 131,900 | 72,000 | 88,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Krish S. Krishnan | Chairman; Chief Executive Officer | Executive Board | 2016 | 59 |
| Kathryn Romano | Chief Accounting Officer; Executive Vice President | Senior Management | 2020 | 43 |
| Suma M. Krishnan | President - Research and Development; Director | Executive Board | 2022 | 59 |
| Christine Wilson | Head - US Sales and Marketing | Senior Management | - | - |
| Stephane Paquette | Vice President - Business Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward